MSB 1.55% 95.0¢ mesoblast limited

Ann: Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease, page-33

  1. 427 Posts.
    lightbulb Created with Sketch. 11887
    As I said in my last post.

    We are virtually the only game in town.

    MSCs have now been proven in China to work on Covid 19 with pretty spectacular results. (albeit small sample size)

    We own the IP.

    Now i will add:

    We have the ability through Lonza to scale up manufacturing like no one else ?

    The announcement talks of “implementing” ..this is not back to the lab stuff.

    The whole world will be rooting for Mesoblast.

    This is about fast tracking a treatment for a BLOCKBUSTER treatment , IRRESPECTIVE of Coronavirus. A treatment for ARDS has enormous potential for both sepsis and COPD.

    If the FDA sanction this i think we are on to something very big indeed.

    The announcement suggests that the Company is very much in discussions with the great and the good !

    This is now a rare “bear market stock” which will have a totally different profile going forward. There will hardly be a fund manager anywhere who will not be looking at this stock over the next month.

    God bless Silviu and his team. What a Company . I am so proud to be a shareholder.

    GLA OP

    DYOR
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
-0.015(1.55%)
Mkt cap ! $1.084B
Open High Low Value Volume
96.5¢ 96.5¢ 94.5¢ $2.433M 2.552M

Buyers (Bids)

No. Vol. Price($)
8 72431 94.5¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 20225 5
View Market Depth
Last trade - 16.10pm 27/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.